LIMN — LIMINATUS PHARMA INC.
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Fundamentals (SEC EDGAR XBRL)
Financials from SEC company facts, point-in-time aligned to each figure’s EDGAR filing date.
| Revenue TTM | Revenue YoY | Net income TTM | Net income YoY | ROE (TTM) | Gross margin | Net margin | P/E (TTM) | P/E pct | P/B | P/B pct |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — |
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
As of Q3 2026, 10 SEC-registered investment managers reported holding LIMN (LIMINATUS PHARMA INC.) in their latest 13F filings, with a combined reported value of $231.37K across 62.02K shares. That is -81.0% by share count (-191.08K shares) versus the previous quarter, while reported value moved +543.7%. Ownership is concentrated: the five largest holders account for 97.2% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 4 opened new positions, 1 added to existing stakes, 5 trimmed, 8 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q3 2026, not real-time trading.
Major shareholders of LIMINATUS PHARMA INC. (LIMN) include Geode Capital Management, JANE STREET GROUP, LLC, Vanguard Group, ranked by reported 13F value among the 29 institutional holders on this page.
LIMN is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 10 | 62.02K | $231.37K | -81.0% |
| Q2 2026 | 14 | 1.07M | $118.28K | -52.2% |
| Q1 2026 | 15 | 1.48M | $253.76K | +340.7% |
| Q4 2025 | 12 | 317.19K | $193.50K | -6.0% |
| Q3 2025 | 10 | 261.92K | $437.44K | +5.1% |
| Q2 2025 | 10 | 204.70K | $2.28M | — |
Over the 6 quarters shown, institutional share counts decreased 70% in aggregate (Q2 2025 → Q3 2026); the largest single-quarter swing was Q1 2026 (+340.7%).
Top Institutional Holders (Q3 2026) — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 41.21K | $153.70K | 0.00% | Reduce | |
| 14.95K | $55.76K | 0.00% | New | |
| 1.94K | $7.22K | 0.00% | New | |
| 1.20K | $4.48K | 0.00% | Reduce | |
| 1.01K | $3.76K | 0.00% | Reduce | |
| 934 | $3.48K | 0.00% | Add | |
| 460 | $1.72K | 0.00% | Reduce | |
| 137 | $536 | 0.00% | New | |
| 100 | $373 | 0.00% | New | |
| 87 | $325 | 0.00% | Reduce |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 14 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 329.33K | $36.00K | 0.03% | Reduce | |
| 221.84K | $24.49K | 0.00% | New | |
| 138.42K | $15.28K | 0.00% | New | |
| 138.42K | $15.28K | 0.00% | Add | |
| 56.09K | $6.19K | 0.00% | Reduce | |
| 50.44K | $5.55K | 0.00% | Hold | |
| 40.22K | $4.44K | 0.00% | New | |
| 26.06K | $3.93K | 0.00% | New | |
| 22.98K | $2.53K | 0.00% | Hold | |
| 16.73K | $1.84K | 0.00% | Reduce | |
| 13.15K | $1.45K | 0.00% | Reduce | |
| 7.09K | $783 | 0.00% | Reduce | |
| 4.29K | $474 | 0.00% | New | |
| 313 | $35 | 0.00% | Reduce |
Q1 2026 — 15 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 677.52K | $116.47K | 0.00% | Add | |
| 350.00K | $60.00K | 0.06% | New | |
| 117.78K | $20.25K | 0.00% | Add | |
| 71.32K | $12.26K | 0.00% | New | |
| 54.58K | $9.39K | 0.00% | Add | |
| 50.44K | $8.68K | 0.00% | New | |
| 34.71K | $5.97K | 0.00% | New | |
| 27.47K | $5.00K | 0.00% | New | |
| 22.98K | $3.95K | 0.00% | New | |
| 22.04K | $3.79K | 0.00% | Add | |
| 19.00K | $3.27K | 0.00% | Hold | |
| 13.25K | $2.28K | 0.00% | Hold | |
| 7.57K | $1.30K | 0.00% | Reduce | |
| 6.77K | $1.16K | 0.00% | Add | |
| 14 | $2 | 0.00% | Reduce |
Q4 2025 — 12 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 73.42K | $44.79K | 0.00% | Hold | |
| 70.93K | $43.27K | 0.00% | New | |
| 65.05K | $39.69K | 0.00% | Add | |
| 35.28K | $21.52K | 0.00% | New | |
| 19.39K | $11.83K | 0.00% | Reduce | |
| 19.00K | $11.59K | 0.00% | Hold | |
| 13.26K | $8.09K | 0.00% | Hold | |
| 11.88K | $7.24K | 0.00% | New | |
| 8.90K | $5.43K | 0.00% | Add | |
| 44 | $27 | 0.00% | Reduce | |
| 31 | $19 | 0.00% | Hold | |
| 1 | $1 | 0.00% | New |
Q3 2025 — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 73.42K | $122.62K | 0.00% | Hold | |
| 63.73K | $106.47K | 0.00% | Hold | |
| 40.53K | $67.68K | 0.00% | Add | |
| 39.63K | $66.19K | 0.00% | New | |
| 19.00K | $31.73K | 0.00% | Hold | |
| 13.26K | $22.14K | 0.00% | Hold | |
| 10.40K | $17.37K | 0.00% | New | |
| 1.85K | $3.09K | 0.00% | Add | |
| 68 | $113 | 0.00% | Add | |
| 31 | $52 | 0.00% | New |
Q2 2025 — 10 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 73.42K | $818.68K | 0.00% | New | |
| 63.84K | $711.83K | 0.00% | New | |
| 31.49K | $351.07K | 0.00% | New | |
| 19.00K | $211.85K | 0.00% | New | |
| 13.26K | $147.79K | 0.00% | New | |
| 2.89K | $32.00K | 0.00% | New | |
| 508 | $5.66K | 0.00% | New | |
| 184 | $2.05K | 0.00% | New | |
| 66 | $735 | 0.00% | New | |
| 52 | $580 | 0.00% | New |
New Positions (Q3 2026)
- JANE STREET GROUP, LLC 14.95K sh · $55.76K
- Morgan Stanley 1.94K sh · $7.22K
- JPMorgan Chase & Co 137 sh · $536
- Cheviot Value Management, LLC 100 sh · $373
Fully Exited (vs previous quarter)
- Cygnus Capital Advisors, LLC sold 329.33K sh · $36.00K
- XTX Topco Ltd sold 221.84K sh · $24.49K
- GEODE CAPITAL MANAGEMENT, LLC sold 138.42K sh · $15.28K
- Citadel Advisors sold 56.09K sh · $6.19K
- Goldman Sachs Group sold 40.22K sh · $4.44K
- StoneX Group Inc. sold 26.06K sh · $3.93K
- Vanguard Personalized Indexing Management, LLC sold 13.15K sh · $1.45K
- BARCLAYS PLC sold 4.29K sh · $474
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Geode Capital Management | 41.21K | 138.42K | 117.78K | 65.05K | 63.73K | 63.84K |
| JANE STREET GROUP, LLC | 14.95K | — | 71.32K | — | 39.63K | — |
| Morgan Stanley | 1.94K | — | — | — | — | — |
| UBS Group AG | 1.20K | 16.73K | 54.58K | 19.39K | 40.53K | 31.49K |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.01K | 50.44K | 50.44K | — | — | — |
| BlackRock Inc | 934 | 313 | 13.25K | 13.26K | 13.26K | 13.26K |
| VANGUARD FIDUCIARY TRUST CO | 460 | 22.98K | 22.98K | — | — | — |
| JPMorgan Chase & Co | 137 | — | — | — | — | — |
| Cheviot Value Management, LLC | 100 | — | — | — | — | — |
| Tower Research Capital LLC (TRC) | 87 | 7.09K | 7.57K | 8.90K | 1.85K | 508 |
| Vanguard Group | — | — | — | 73.42K | 73.42K | 73.42K |
| STATE STREET CORP | — | — | 19.00K | 19.00K | 19.00K | 19.00K |
| Citadel Advisors | — | 56.09K | 677.52K | 70.93K | — | — |
| Cygnus Capital Advisors, LLC | — | 329.33K | 350.00K | — | — | — |
| ROYAL BANK OF CANADA | — | — | — | — | — | 2.89K |
| XTX Topco Ltd | — | 221.84K | — | — | — | — |
| Two Sigma Investments | — | — | — | 35.28K | — | — |
| Squarepoint Ops LLC | — | — | — | — | 10.40K | — |
| GEODE CAPITAL MANAGEMENT, LLC | — | 138.42K | — | — | — | — |
| TWO SIGMA SECURITIES, LLC | — | — | 22.04K | 11.88K | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold LIMN?
As of 2026-Q3, 10 institutional funds reported holding LIMN (LIMINATUS PHARMA INC.) in SEC 13F filings, with a combined reported value of $231.37K.
How many shares of LIMN do institutions own?
13F filers reported 62.02K shares of LIMN, worth $231.37K in aggregate at the end of 2026-Q3.
Is institutional ownership of LIMN rising or falling?
Share counts moved -81.0% versus the prior quarter — distribution.
Who are the top institutional holders of LIMN?
The largest 13F holders are Geode Capital Management, JANE STREET GROUP, LLC, Vanguard Group, Cygnus Capital Advisors, LLC, ROYAL BANK OF CANADA; the top 25 are ranked at the top of this page.
Who are the major shareholders of LIMINATUS PHARMA INC.?
The major shareholders of LIMINATUS PHARMA INC. (LIMN) by reported 13F value are Geode Capital Management, JANE STREET GROUP, LLC, Vanguard Group, Cygnus Capital Advisors, LLC, ROYAL BANK OF CANADA, among 29 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.